Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Conditions:   Tuberculosis;   Tuberculosis, Pulmonary Interventions:   Drug: 1800 mg TBI-223;   Drug: 2400mg TBI-223;   Drug: 3000mg TBI-223;   Drug: TBI-223 Placebo Sponsor:   Global Alliance for TB Drug Development Recruiting

Source: ClinicalTrials.gov - April 29, 2021 Category: Research Source Type: clinical trials